Kayothera
Wednesday, June 05, 2024
Company Presentation
![Platform for Therapeutics](https://cdn.asp.events/CLIENT_BIO_7BB99CBA_BAD1_B8C8_CF9F25DA29A80CC6/sites/BIOIC-2024/media/icons/seminars/blank.png)
Company Presentation Theater 4
Kayothera has developed a pipeline of first-in-class, exceptionally safe, oral retinoid pathway antagonists that offer a unique platform to treat various cardiometabolic diseases and cancer. Therapies in Kayothera’s pipeline inhibit distinct enzymes in the retinoid pathway that drive disease progression in type 2 diabetes and obesity, while other pipeline therapies reverse immune suppression in multiple genetically defined and high-need cancer types. The lead program, KAYO-1609, is currently in IND-enabling studies to support a Phase 1 trial in early 2025 in healthy patients, while additional programs are slated for clinical entry in 2026.
![Kayothera](https://www.abstractscorecard.com/uploads/Tasks/upload/21754/XDQDGWMO-1810362-1-JPG.png)
Company Website:
https://kayothera.com
Lead Product in Development:
Kayo-1609
Number Of Unlicensed Products (For Which You Are Seeking Partners):
four
Company HQ City
Seattle
Company HQ State
Washington
Company HQ Country
United States
CEO/Top Company Official
Thong Q. Le
Development Phase of Primary Product
Pre-Clinical
Primary Speaker